Get access to our best features
Get Started
SubscribeLogin
Get access to our best features
Get Started
Published

New York Medical College Clinical Trial Becomes First to Administer Novel Inhaled mRNA Therapy to a Patient with Cystic Fibrosis in the United States - River Journal Online - News for Tarrytown, Sleepy Hollow, Irvington, Ossining, Briarcliff Manor, Croton

Summary by riverjournalonline.com
New York Medical College (NYMC), in collaboration with ReCode Therapeutics, a clinical-stage genetic medicines company, today announced that the first participant has been dosed with RCT2100 — a novel investigational inhaled messenger RNA (mRNA) therapy for people with cystic fibrosis (CF). This clinical trial aims to assess the safety and tolerability of RCT2100, providing new hope for people who do not respond to existing CFTR modulator treatm…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Valhalla

Valhalla

Valencia, Spain

Valencia, Spain

Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2025 Snapwise Inc
News
For You
Search
BlindspotLocal